Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1286 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Genta initiates prostate cancer drug trial

The study will assess tesetaxel as both first- and second-line chemotherapy. The study will evaluate two discrete populations: men with hormone/castrate-resistant prostate cancer, who have not previously received

QLT retinoid drug receives EMA positive opinions

QLT091001 works as a replacement for 11-cis-retinal, a key biochemical component of the visual retinoid cycle, and is used to treat the inherited retinal degenerative diseases Leber Congenital

BioCryst reports net loss in 2010 fourth quarter

Fourth quarter 2010 R&D expenses decreased to $23.6m from $31.6m in last year, driven by lower development costs associated with the peramivir and forodesine clinical programs. Total revenues